Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma - Archive ouverte HAL Access content directly
Journal Articles Cancer Research Year : 2023

Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma

Guillaume Davidson
  • Function : Author
Yann Vano
  • Function : Author
Reza T. Elaidi
  • Function : Author
Virginie Verkarre
  • Function : Author
Cheng-Ming Sun
  • Function : Author
Christine Chevreau
  • Function : Author
Mostefa Bennamoun
  • Function : Author
Thibault Tricard
  • Function : Author
Wolf H. Fridman
  • Function : Author
Catherine Sautes-Fridman
  • Function : Author
Xiaoping Su
  • Function : Author
Stéphane M. Oudard
  • Function : Author

Abstract

Immune checkpoint inhibitors (ICI) represent the cornerstone for the treatment of patients with metastatic clear cell renal cell carcinoma (ccRCC). Despite a favorable response for a subset of patients, others experience primary progressive disease, highlighting the need to precisely understand the plasticity of cancer cells and their cross-talk with the microenvironment to better predict therapeutic response and personalize treatment. Single-cell RNA sequencing of ccRCC at different disease stages and normal adjacent tissue (NAT) from patients identified 46 cell populations, including 5 tumor subpopulations, characterized by distinct transcriptional signatures representing an epithelial-to-mesenchymal transition gradient and a novel inflamed state. Deconvolution of the tumor and microenvironment signatures in public data sets and data from the BIONIKK clinical trial (NCT02960906) revealed a strong correlation between mesenchymal-like ccRCC cells and myofibroblastic cancer-associated fibroblasts (myCAF), which are both enriched in metastases and correlate with poor patient survival. Spatial transcriptomics and multiplex immune staining uncovered the spatial proximity of mesenchymal-like ccRCC cells and myCAFs at the tumor-NAT interface. Moreover, enrichment in myCAFs was associated with primary resistance to ICI therapy in the BIONIKK clinical trial. These data highlight the epithelial-mesenchymal plasticity of ccRCC cancer cells and their relationship with myCAFs, a critical component of the microenvironment associated with poor outcome and ICI resistance. SIGNIFICANCE: Single-cell and spatial transcriptomics reveal the proximity of mesenchymal tumor cells to myofibroblastic cancer-associated fibroblasts and their association with disease outcome and immune checkpoint inhibitor response in clear cell renal cell carcinoma. Humans Gene Expression Profiling Prognosis Kidney Neoplasms Immunotherapy Tumor Microenvironment Clinical Trials as Topic
No file

Dates and versions

hal-04398935 , version 1 (16-01-2024)

Identifiers

Cite

Guillaume Davidson, Alexandra Helleux, Yann Vano, Veronique Lindner, Antonin Fattori, et al.. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma. Cancer Research, 2023, 83 (17), pp.2952-2969. ⟨10.1158/0008-5472.CAN-22-3034⟩. ⟨hal-04398935⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More